SCHEMBL20248904

SCHEMBL20248904

c1ccc(-c2c3cc(-c4ccc(-c5nnc(-c6ccc(-c7cc8c(-c9ccccc9)c9sccc9c(-c9ccccc9)c8s7)cc6)o5)cc4)sc3c(-c3ccccc3)c3ccsc23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 13/20 0.44
▸ RAB9A P51151 13/20 0.44
▸ SMN1; SMN2 Q16637 7/20 0.44
▸ HPGD P15428 4/20 0.41
▸ TSHR P16473 3/20 0.41
▸ NFKB1 P19838 3/20 0.41
▸ NFKB2 Q00653 3/20 0.41
▸ RELA Q04206 3/20 0.41
▸ TP53 P04637 2/20 0.41
▸ MECP2 P51608 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ ATR Q13535 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20248872 0.83 ADORA2A (0.46) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL20248873 0.82 ADORA2A (0.45) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL20248901 0.80 MEN1 (0.43) HPGDMEN1KMT2AALDH1A1KDM4E
SCHEMBL20248905 0.79 KDM4E (0.44) SMN1; SMN2HPGDTSHRMEN1KMT2A
SCHEMBL20248908 0.79 ADORA1 (0.43) RAB9AHPGDMEN1KMT2APOLB
SCHEMBL20248869 0.79 ADORA2A (0.42) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL20248903 0.78 ADORA1 (0.45) NPC1RAB9AMEN1KMT2APOLB
SCHEMBL20248868 0.78 ADORA2A (0.44) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL20248879 0.78 PTP4A3 (0.39) POLBCA1CA2CA9
SCHEMBL20254282 0.78 XDH (0.32) MEN1KMT2APOLBKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10347846-B2 Organic compound for organic EL device and using the same LUMINESCENCE TECHNOLOGY CORP. (TW) 2019-07-09 — — US disclosed
US-20180166640-A1 ORGANIC COMPOUND FOR ORGANIC EL DEVICE AND USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2018-06-14 — — US disclosed
US-20180166640-A1 ORGANIC COMPOUND FOR ORGANIC EL DEVICE AND USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2018-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10347846-B2 Organic compound for organic EL device and using the same L1CAM, ESR1, XPO4 NPC1 242/4885RAB9A 3071/4885SMN1; SMN2 2181/4885
US-20180166640-A1 ORGANIC COMPOUND FOR ORGANIC EL DEVICE AND USING THE SAME L1CAM, ESR1, XPO4 NPC1 242/4885RAB9A 3071/4885SMN1; SMN2 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback